Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Biomarkers in Medicine

Volumn 6, Issue 3, 2012, Pages 349-362

  Crona, Daniel ^a   Innocenti, Federico ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

5 fluorouracil; 6 mercaptopurine; bevacizumab; cetuximab; dosing; erlotinib; irinotecan; pharmacogenetics; survival; toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; MERCAPTOPURINE; NILOTINIB; PANITUMUMAB; SUNITINIB; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVERSE DRUG REACTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG ACTIVATION; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOXICITY; GASTROESOPHAGEAL CANCER; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GERMLINE MARKER; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DRUG MONITORING; GERM-LINE MUTATION; HUMANS; KNOWLEDGE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84862848783     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.19     Document Type: Review

References (98)

1. Hoskins JM, Carey LA, Mcleod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
2. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).
3. Evans WE, Mcleod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
4. Sassi G, Striano B, Merlo UA. A reporting system for the assessment of chemotherapy toxicity. J. Oncol. Pharm. Pract. 11(2), 63-67 (2005).
5. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in Phase I cancer clinical trials. J. Natl Cancer Inst. 101(10), 708-720 (2009).
6. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 4(2), e4439 (2009).
7. Bennett CL, Nebeker JR, Yarnold PR et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch. Intern. Med. 167(10), 1041-1049 (2007).
8. No authors listed. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J. Clin. Oncol. 16(11), 3537-3541 (1998).
9. Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 69(1), 99-106 (2011).
10. Hoskins JM, Carey LA, Mcleod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
11. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).
12. Evans WE, Mcleod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
13. Sassi G, Striano B, Merlo UA. A reporting system for the assessment of chemotherapy toxicity. J. Oncol. Pharm. Pract. 11(2), 63-67 (2005).
14. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in Phase I cancer clinical trials. J. Natl Cancer Inst. 101(10), 708-720 (2009).
15. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 4(2), e4439 (2009).
16. Bennett CL, Nebeker JR, Yarnold PR et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch. Intern. Med. 167(10), 1041-1049 (2007).
17. No authors listed. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J. Clin. Oncol. 16(11), 3537-3541 (1998).
18. Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 69(1), 99-106 (2011).
19. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
20. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol. 28(6), 949-954 (2010).
21. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J. Clin. Oncol. 28(26), 4029-4037 (2010).
22. Innocenti F, Schilsky RL. Translating the cancer genome into clinically useful tools and strategies. Dis. Models Mech. 2(9-10), 426-429 (2009).
23. Marsh S, Mcleod HL. Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. 15(1), R89-R93 (2006).
24. Paugh SW, Stocco G, Mccorkle JR, Diouf B, Crews KR, Evans WE. Cancer Pharmacogenomics. Clin. Pharmacol. Ther. 90(3), 461-466 (2011).
25. Houtsma D, Guchelaar HJ, Gelderblom H. Pharmacogenetics in oncology: a promising field. Curr. Pharm. Des. 16(2), 155-163 (2010).
26. Yong WP, Innocenti F, Ratain MJ. The role of Pharmacogenetics in cancer therapeutics. Br. J. Clin. Pharmacol. 62(1), 35-46 (2006).
27. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166-178 (2006).
28. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22(47), 7403-7413 (2003).
29. Kishi S, Cheng C, French D et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10), 4151-4157 (2007).
30. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
31. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998).
32. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, Fisher RA. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 30(2), 476-484 (1999).
33. Ramirez J, Mirkov S, Zhang W et al. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J. 8(2), 152-161 (2008).
34. Iyer L, Hall D, Das S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65(5), 576-582 (1999).
35. Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101(4), 847-854 (1998).
36. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9), 1916-1924 (2005).
37. Lyman GH. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Curr. Opin. Hematol. doi:10.1097/MOH. 0b013e328340dc51 (2010) (Epub ahead of print).
38. Donnan JR, Ungar WJ, Mathews M, Rahman P. Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Ther. Drug Monit. 33(2), 192-199 (2011).
39. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
40. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8), 1211-1221 (2006).
41. Watson RG, Mcleod HL. Pharmacogenomic contribution to drug response. Cancer J. 17(2), 80-88 (2011).
42. Salgueiro N, Veiga I, Fragoso M et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genet. Med. 6(2), 102-107 (2004).
43. Ahluwalia R, Freimuth R, Mcleod HL, Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin. Chem. 49(10), 1661-1664 (2003).
44. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 ± 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002).
45. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14±1G>A mutation. Int. J. Cancer 101(3), 253-258 (2002).
46. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
47. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9(3), 267-274 (2008).
48. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 4(2), 107-119 (2009).
49. Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 8(2), 129-138 (2008).
50. Huang CL, Yang CH, Yeh KH et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64(3), 346-351 (2009).
51. Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26(7), 1119-1127 (2008).
52. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64(24), 9139-9143 (2004).
53. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24(9), 1363-1369 (2006).
54. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am. J. Hypertens. 23(5), 460-468 (2010).
55. Jubb AM, Hurwitz HI, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24(2), 217-227 (2006).
56. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
57. Kim JJ, Vaziri SA, Rini BI et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118(7), 1946-1954 (2011).
58. Massacesi C, Terrazzino S, Marcucci F et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5), 1007-1016 (2006).
59. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004).
60. Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J. Int. Med. Res. 38(3), 870-883 (2010).
61. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
62. Zhang X, Soong R, Wang K et al. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem. Cell Biol. 85(3), 337-346 (2007).
63. Yu J, Mcleod HL, Ezzeldin HH, Diasio RB. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res. 12(12), 3864; author reply 3864 (2006).
64. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11(24 Pt 1), 8699-8705 (2005).
65. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. 27(8), 432-437 (2006).
66. CAMPTOSAR®, package insert. Solution for intravenous injection, irinotecan hydrochloride solution for intravenous injection. Pfizer Ltd. NY, USA (2009).
67. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119(6), 985-989 (1991).
68. Schmiegelow K, Forestier E, Hellebostad M et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24(2), 345-354 (2010).
69. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107(2), 843-844 (2006).
70. Schmiegelow K, Heyman M, Kristinsson J et al. Oral methotrexate/6- mercaptopurine may be superior to a multidrug LSA2L2 maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J. Pediatr. Hematol. Oncol. 31(6), 385-392 (2009).
71. Stocco G, Cheok MH, Crews KR et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85(2), 164-172 (2009).
72. Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin. Drug Saf. 9(1), 23-37 (2010).
73. Pui CH, Sandlund JT, Pei D et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104(9), 2690-2696 (2004).
74. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
75. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
76. Toffoli G, Cecchin E, Gasparini G et al. Genotype-driven Phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(5), 866-871 (2010).
77. Marcuello E, Paez D, Pare L et al. A genotype-directed Phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105(1), 53-57 (2011).
78. Satoh T, Ura T, Yamada Y et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 102(10), 1868-1873 (2011).
79. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin. Cancer Res. 16(15), 3832-3842 (2010).
80. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, Mcleod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
81. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
82. Liu CY, Chen PM, Chiou TJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112(9), 1932-1940 (2008).
83. Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117(14), 3156-3162 (2011).
84. Gibson TB, Ranganathan A, Grothey A. Randomized Phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer 6(1), 29-31 (2006).
85. Nie Q, Wang Z, Zhang GC et al. The epidermal growth factor receptor intron 1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur. J. Pharmacol. 570(1-3), 175-181 (2007).
86. Gregorc V, Hidalgo M, Spreafico A et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin. Pharmacol. Ther. 83(3), 477-484 (2008).
87. Dassoulas K, Gazouli M, Rizos S et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48(6), 563-569 (2009).
88. Kim JG, Chae YS, Sohn SK et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin. Cancer Res. 14(1), 62-66 (2008).
89. Loupakis F, Ruzzo A, Salvatore L et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11, 247 (2011).
90. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'donnell CJ, De Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24(24), 2938-2939 (2008).
91. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 94(12), 1823-1832 (2006).
92. Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin. Oncol. 38(2), 186-195 (2011).
93. Fine JP, Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999).
94. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 61(1), 223-229 (2005).
95. Lee JJ, Feng L, Reshef DS et al. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev. Res. 3(6), 738-744 (2010).
96. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 26(14), 2373-2378 (2008).
97. Pui CH, Pei D, Sandlund JT et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(31), 7936-7941 (2005).
98. Swen JJ, Nijenhuis M, De Boer A et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).